1. Home
  2. UTHR vs WES Comparison

UTHR vs WES Comparison

Compare UTHR & WES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • WES
  • Stock Information
  • Founded
  • UTHR 1996
  • WES 2007
  • Country
  • UTHR United States
  • WES United States
  • Employees
  • UTHR N/A
  • WES N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • WES Natural Gas Distribution
  • Sector
  • UTHR Health Care
  • WES Utilities
  • Exchange
  • UTHR Nasdaq
  • WES Nasdaq
  • Market Cap
  • UTHR 14.4B
  • WES 14.4B
  • IPO Year
  • UTHR 1999
  • WES 2008
  • Fundamental
  • Price
  • UTHR $297.02
  • WES $39.61
  • Analyst Decision
  • UTHR Buy
  • WES Hold
  • Analyst Count
  • UTHR 13
  • WES 5
  • Target Price
  • UTHR $383.08
  • WES $40.40
  • AVG Volume (30 Days)
  • UTHR 551.5K
  • WES 896.1K
  • Earning Date
  • UTHR 07-30-2025
  • WES 08-06-2025
  • Dividend Yield
  • UTHR N/A
  • WES 9.22%
  • EPS Growth
  • UTHR 18.86
  • WES N/A
  • EPS
  • UTHR 25.10
  • WES 3.34
  • Revenue
  • UTHR $2,994,100,000.00
  • WES $3,634,610,000.00
  • Revenue This Year
  • UTHR $14.30
  • WES $5.65
  • Revenue Next Year
  • UTHR $6.32
  • WES $3.65
  • P/E Ratio
  • UTHR $11.79
  • WES $11.81
  • Revenue Growth
  • UTHR 19.84
  • WES 11.48
  • 52 Week Low
  • UTHR $266.98
  • WES $33.60
  • 52 Week High
  • UTHR $417.82
  • WES $43.33
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 51.32
  • WES 60.58
  • Support Level
  • UTHR $286.68
  • WES $38.80
  • Resistance Level
  • UTHR $301.75
  • WES $39.57
  • Average True Range (ATR)
  • UTHR 6.73
  • WES 0.71
  • MACD
  • UTHR 1.81
  • WES 0.10
  • Stochastic Oscillator
  • UTHR 77.16
  • WES 93.60

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About WES Western Midstream Partners LP Common Units Representing Limited Partner Interests

Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.

Share on Social Networks: